CD274 and neoplasm: Although major efforts have been made to identify biomarkers allowing to predict immunotherapy response, such as tumor mutation burden and PD-L1 protein expression, the population of patients who benefit from immunotherapy has remained very limited because these biomarkers incompletely reflect the heterogeneous tumor microenvironment (TME) 5.